# PRISM MarketView Highlights Seven Small-Cap Lung Cancer Developers for Lung Cancer Awareness Month

- Published: 2026-11-16
- Author: [BiotechNews.io](https://biotechnews.io/author/biotechnews-io.md)
- Topics: [News](https://biotechnews.io/news.md)
- Source: https://biotechnews.io/news/prism-marketview-highlights-seven-small-cap-lung-cancer-developers-for-lung-cancer-awarene/
- Publication: Biotech News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://biotechnews.io/editorial-policy/

*Feature examines how survival data, FDA decisions and new diagnostics are putting clinical endpoints in focus for small-cap lung cancer companies*

![Chest X-ray beside the PRISM MarketView logo, a purple awareness ribbon and the text “Lung Cancer Awareness Month: Survival Data in Focus.”](https://ml.globenewswire.com/Resource/Download/b1585272-bd54-4c1f-9906-10b0b20882a4/image1.png)

NEW YORK, Nov. 16, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.globenewswire.com/Tracker?data=jDI7_Tua3kulafm4iMqlPK8Zs3wo_q8kmMhrzO_o68O1ccTarqEcyRGwA3uWwhcpM1ldrUQd1DczS0BK6I0K8VIR1oEarE1NvtJVsGZDN38=" rel="nofollow">PRISM MarketView</a>, a financial media platform covering small-cap public companies through 27 thematic indexes, today published a <a href="https://www.globenewswire.com/Tracker?data=I17mLEmLRy_BsBUYKEKLnMwCF68nInqtTVMCMrX8UY70LuDpojrMwrO4O4wK8OcR1YS4_B6vVGjwC8PvHiG_iZh8OplTUDjj65k47fzQSNdD4hHbMO1Lia3_3f1Mfo2Mn0rUuwo38qIuOKQ0RJJmhvYa2FYvfPcThgwK16TjniRWzHWPLQLF9SQycElv-FEJUyHSTjWczRUGFvPnhvb833HDw01ZKlLInRQbkYYZFEs=" rel="nofollow">Lung Cancer Awareness Month</a> feature on seven small-cap companies developing therapies and diagnostics for lung cancer, the leading cause of cancer death in the U.S.

The feature follows the FDA's decision not to approve a PD-1xVEGF bispecific antibody in EGFR-mutated lung cancer after the agency concluded the data could not establish effectiveness without a statistically significant survival benefit. The decision has put clinical endpoints in focus for smaller developers working in the disease.

Candel Therapeutics (<a href="https://www.globenewswire.com/Tracker?data=33672D-NPUIRmpVbpFlD2hgvsuGhHqCf8VRpGuFjwT5nqhAerDffDZVOfoQjTUW-IYcpr6KkkRsy36BqB_0PK7RZKXsp56l-gbNheXyZy5US7VUmI-cezI-nQVMC813e3mZsNJXLXjbjkSVtV0vCpg==" rel="nofollow">NASDAQ: CADL</a>) and MAIA Biotechnology (<a href="https://www.globenewswire.com/Tracker?data=FkpuvE8J1VihyTlojc68NKiDc5wwgOx6RlMfkgO0w35DWMjf7NzegOQEZuXjkOSjg7QwHnO7ts_oaUbUUmIABhvM_iT1d6_KZwt2dPmsbquOCsSWj71cFi71moZkkhSO" rel="nofollow">NYSE American: MAIA</a>) are running Phase 3 trials that use overall survival as their primary endpoint. Cullinan Therapeutics (<a href="https://www.globenewswire.com/Tracker?data=33672D-NPUIRmpVbpFlD2jlWwyyJaWINjAemuRc23HgceHPnKlVwlSiTHfRAMlnSwodkhL2I0MpYeHqqMqcIViBxeiCVvaO6KqB-WZaDZ2g=" rel="nofollow">NASDAQ: CGEM</a>) and partner Taiho Oncology are awaiting an FDA decision on zipalertinib, with a target action date of February 27, 2027. Crescent Biopharma (<a href="https://www.globenewswire.com/Tracker?data=33672D-NPUIRmpVbpFlD2iPdnFg6G9zFkStR7F2Ttk8iH1MniB1kRCEfySHNxAR9CFel0RuubAmU2w7DND36F8kCggHjrBsgqoHKaRiIU1E=" rel="nofollow">NASDAQ: CBIO</a>) expects proof-of-concept data for its PD-1xVEGF bispecific CR-001 in the first quarter of 2027, and Tango Therapeutics (<a href="https://www.globenewswire.com/Tracker?data=33672D-NPUIRmpVbpFlD2kaNoY7KYEUILdJEXYZ1_fO9eMK55YK6pGXogP0tAsYEax-zCoCLMxamHJa3E2pSKp3qnATCLgkjUIV5nxVFRs9fB3ZoIXu0-osxuBX6kwMJT5USatxJszF7T4FUUUgXDQ==" rel="nofollow">NASDAQ: TNGX</a>) plans to disclose lung cancer data for vopimetostat in January 2027.

Personalis (<a href="https://www.globenewswire.com/Tracker?data=33672D-NPUIRmpVbpFlD2i6QhXRzgSeUhSH3Z4BEWbOQItUm16hNPsg_1KOpdR-ekWvxUrdi2VzUa6sSijcxeMNaLNvX5iJGFCjW-cDAySmp8UHEztfEXyo8KQzfsvqv" rel="nofollow">NASDAQ: PSNL</a>) secured Medicare coverage for its NeXT Personal residual disease test in stage I to III non-small cell lung cancer, and bioAffinity Technologies (<a href="https://www.globenewswire.com/Tracker?data=33672D-NPUIRmpVbpFlD2g9Y4BQorba27_kRaFPjd2T0qTnc-hI1sCqIooS24iuJL24oDWa-AgOo2PRBrg9881u149-Zd5p891RTUkOcC4v_5GQpoZ5Cmpdjaxnt4eaSmkBSmbKcUNWM81sugEvRxA==" rel="nofollow">NASDAQ: BIAF</a>) is extending its CyPath Lung test to monitoring survivors after treatment.

Read the full article on PRISM MarketView: <a href="https://www.globenewswire.com/Tracker?data=GAWKB031veIQ0EM7GUARdKyWlh30mUciUHQpRICFW8ti-oe2_LvbcnDx9XQsHKq_pjxz6JDecRkacrpxjQKSAy0r3p6jAFne3_HTrj2VsTUrLb8Ld7fICULRtM1xIAwHiPGFwWlUEjZ7wKWDYS-a2S_WkA-5D0dsba2J4D9mqBqzUAC2GSqbwfaZXIeCPAVT4c43VMUGlIH0ZTg3yHgZgr__PJoMqH4udGfgioUwwFaqaXeQwAGbgxawHn9B0tA-dpCYitr1nSyGCbp_InQGhc-bOVAbS6DpgeegcviYW1e9fz-HyEnoBkh5kp_GyTBuUnNzi2Sg-zP8dgg7cPrCXCkRUNCGNgoTvCsqQyg3yXA=" rel="nofollow">https://prismmarketview.com/fda-rejection-of-summits-lung-cancer-drug-puts-survival-data-at-the-center-for-small-caps/</a>

**About PRISM MarketView**

PRISM MarketView is a financial media and index publishing platform for investors seeking small-cap opportunities. Since 2020, PRISM has covered emerging growth companies through daily news, analysis and 27 thematic small-cap indexes spanning biotech, medtech, AI, energy and more. Learn more at <a href="https://www.globenewswire.com/Tracker?data=F9Pz-gFQAuxbyLHhn13fa0oCWwwChWD2kfESQS76P8HLBcqTWYeMJ8ihfGjn6-YPgqOsacp6q0zRP1AyIQ0IcTldQuZ8Hoj96x822kE4xDM=" rel="nofollow">prismmarketview.com</a>.

Follow PRISM MarketView on <a href="https://www.globenewswire.com/Tracker?data=mZ0hwU5_WYLAnB6SP-Jyw2jf0X7T0H44A0dO8UkaZQG04iWWFngv-Li2tn1vp1r1i2To_9WON5k84spHZmViTQ==" rel="nofollow">X</a>, <a href="https://www.globenewswire.com/Tracker?data=hhC4ckEFb6_5ORH3XFKd7CJD5m9Y6_dluJy7gPw6dsinr5MdnObdBkakSqnjsVasaGNDw1GGuzxWjXMFn6z6UWBvSgT0vPictW0SAWds45XXKhg757cmJhvgAxAOmIcu" rel="nofollow">LinkedIn</a>, <a href="https://www.globenewswire.com/Tracker?data=0vyoNkkeeAF9ECdKQkT-hjmaCQtIiE1bIlZXPABFi66P-AkrTbHikdM0OJVR01oRygq2Rd81VXdxzHQ3ErUw7MQ9-Nne-kBOnrx3FR6nY_c=" rel="nofollow">Instagram</a>, <a href="https://www.globenewswire.com/Tracker?data=LdRaaioeUlxtO5nE0940UV01sRPLJ5xA8kNC-v1z28KnJea0aZ2qQ2WRlsaZ9VX_weyRBO7W-P5rLjCyahdxBhCI3tTftpHpO976y-WdK2w=" rel="nofollow">TikTok</a> and <a href="https://www.globenewswire.com/Tracker?data=xz9rpHFY4-51Izb1S6318zNRnD7hvJpsEuY3naYHh1xPljtbL6zMqCcgaC4vAVc9_M2Rvx0eDeR4gsOPnIBeU5nWwQDgQFrNDx7NzkShzy1BfrirLZ3Orzww15ihYHeC" rel="nofollow">YouTube</a>.

*PRISM MarketView does not provide investment advice.*

**Media Contact**  
<a href="https://www.globenewswire.com/Tracker?data=70gEMg8wKMJJJGuQ8vgATPxWi4B4tmisaxvggBIq8vhkQYkiWZVUZkWPyXiOgKp85_Di_UHhzHVNE8WS-WKpJETaaGn2UGvNve37XmRuLDYNTxlJut3c9o5z4RH5ZJ2n" rel="nofollow">info@prismmarketview.com</a>  
646-863-6341

A photo accompanying this announcement is available at <a href="https://www.globenewswire.com/Tracker?data=GAWKB031veIQ0EM7GUARdGAdVpq7Q67j4lEkGwM22cmNy07eyHv1PrEDZDIUX6HDPYyB3VAaLCuGYlzG9L8qaBzEt_MoLhx_6Aoisled7IOGh2F11WX9F5BAw9ulmT3NZO21NMGlVL-0KhA-TPZ0NrAZzxjtvjwHOnvZd0fB_BoSnLZWSnu030jULYJjHLZbC3FvL2OupDL6xjVIcl1jOIld7arJhY2xd8sJlVPYarzrrQpM2CzD1IS-TQWEVYAn4S2aBKPUtC3uA-MnKVzZKg==" rel="nofollow">https://www.globenewswire.com/NewsRoom/AttachmentNg/b1585272-bd54-4c1f-9906-10b0b20882a4</a>

  
![](https://ml.globenewswire.com/media/NTUzMjBlYjgtMjMyOS00NzU2LTgzZWMtM2JiY2I2MDNiZjdmLTUwMDEyMDc4Mi0yMDI2LTExLTE2LWVu/tiny/PRISM-MarketView.png)

## Related

- [Non-Animal Alternative Testing - Global Strategic Business Report 2026: Capitalize on 13.3% CAGR and $4.7B by 2032 as Abbott, Charles River, Emulate, Evotec, and Bio-Rad Reshape Testing](https://biotechnews.io/news/non-animal-alternative-testing-global-strategic-business-report-2026-capitalize-on-13-3-ca.md)
- [Veterinary Molecular Diagnostics Market Size, Share, and Trends - Global Forecast to 2036 | Point-of-Care PCR, Sequencing, and Genomic Testing Drive 9.2% CAGR Toward USD 2.13 Billion](https://biotechnews.io/news/veterinary-molecular-diagnostics-market-size-share-and-trends-global-forecast-to-2036-poin.md)
- [Global Human Liver Model Market Report 2026: Size, Share, Trends, and Forecast to 2030 | 3D Models and Organ-on-a-Chip Propel 15.03% CAGR and US$3.81 Billion Opportunity](https://biotechnews.io/news/global-human-liver-model-market-report-2026-size-share-trends-and-forecast-to-2030-3d-mode.md)
- [Mice Model - Global Strategic Business Report 2026: Capitalize on a $3.4 Billion Market by 2032 as Charles River, LabCorp, Taconic Biosciences and The Jackson Laboratory Accelerate CRISPR](https://biotechnews.io/news/mice-model-global-strategic-business-report-2026-capitalize-on-a-3-4-billion-market-by-203.md)
